Aldosterone inhibits inducible nitric oxide synthase in neonatal rat cardiomyocytes

Endocrinology

Volumn 144, Issue 5, 2003, Pages 1712-1717

  Chun, Tae Yon ^a,c   Bloem, Laura J ^b   Pratt, J Howard ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c Department of Medicine ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; DEXAMETHASONE; INTERLEUKIN 1; MESSENGER RNA; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; SPIRONOLACTONE; TRANSFORMING GROWTH FACTOR BETA; ALDOSTERONE ANTAGONIST; GLUCOCORTICOID; INDUCIBLE NITRIC OXIDE SYNTHASE; NOS2 PROTEIN, RAT; TGFB1 PROTEIN, RAT; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL CELL; ARTICLE; CELL DEATH; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; FIBROSIS; HEART FAILURE; HEART FUNCTION; HEART MUSCLE CELL; HORMONE ACTION; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; ANIMAL; CELL CULTURE; DOSE RESPONSE; DRUG ANTAGONISM; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PHYSIOLOGY; PROTEIN PROCESSING; RAT; SPRAGUE DAWLEY RAT;

ALDOSTERONE; ALDOSTERONE ANTAGONISTS; ANIMALS; ANIMALS, NEWBORN; CELLS, CULTURED; DEXAMETHASONE; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION; GLUCOCORTICOIDS; MYOCYTES, CARDIAC; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; PROTEIN PROCESSING, POST-TRANSLATIONAL; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; SPIRONOLACTONE; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1;

EID: 0038410160     PISSN: 00137227     EISSN: None     Source Type: Journal    
DOI: 10.1210/en.2002-220956     Document Type: Article

References (33)

1. Lombes M, Oblin ME, Gasc JM, Baulieu EE, Farman N, Bonvalet JP 1992 Immunohistochemical and biochemical evidence for a cardiovascular mineralocorticoid receptor. Circ Res 71:503-510
2. Lombes M, Alfaidy N, Eugene E, Lessana A, Farman N, Bonvalet JP 1995 Prerequisite for cardiac aldosterone action. Mineralocorticoid receptor and 11 β-hydroxysteroid dehydrogenase in the human heart. Circulation 92:175-182
3. Pearce P, Funder JW 1987 High affinity aldosterone binding sites (type I receptors) in rat heart. Clin Exp Pharmacol Physiol 14:859-866
4. Rocha R, Chander PN, Khanna K, Zuckerman A, Stier Jr CT 1998 Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension 31:451-458
5. Rocha R, Stier Jr CT, Kifor I, Ochoa-Maya MR, Rennke HG, Williams GH, Adler GK 2000 Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. Endocrinology 141:3871-3878
6. Brilla CG, Pick R, Tan LB, Janicki JS, Weber KT 1990 Remodeling of the rat right and left ventricles in experimental hypertension. Circ Res 67:1355-1364
7. Rossi GP, Sacchetto A, Visentin P, Canali C, Graniero GR, Palatini P, Pessina AC 1996 Changes in left ventricular anatomy and function in hypertension and primary aldosteronism. Hypertension 27:1039-1045
8. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J 1999 The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341:709-717
9. Harding P, Carretero OA, LaPointe MC 1995 Effects of interleukin-1β and nitric oxide on cardiac myocytes. Hypertension 25:421-430
10. Singh K, Balligand JL, Fischer TA, Smith TW, Kelly RA 1995 Glucocorticoids increase osteopontin expression in cardiac myocytes and microvascular endothelial cells. Role in regulation of inducible nitric oxide synthase. J Biol Chem 270:28471-28478
11. Zhang H, Chen X, Teng X, Snead C, Catravas JD 1998 Molecular cloning and analysis of the rat inducible nitric oxide synthase gene promoter in aortic smooth muscle cells. Biochem Pharmacol 55:1873-1880
12. Fiebeler A, Schmidt F, Muller DN, Park JK, Dechend R, Bieringer M, Shagdarsuren E, Breu V, Haller H, Luft FC 2001 Mineralocorticoid receptor affects AP-1 and nuclear factor-κB activation in angiotensin II-induced cardiac injury. Hypertension 37:787-793
13. Schini-Kerth VB, Boese M, Busse R, Fisslthaler B, Mulsch A 1997 N-α-tosyl-L-lysine chloromethylketone prevents expression of iNOS in vascular smooth muscle by blocking activation of NF-κB. Arterioscler Thromb Vasc Biol 17:672-679
14. Zhang HY, Phan SH 1999 Inhibition of myofibroblast apoptosis by transforming growth factor β(1). Am J Respir Cell Mol Biol 21:658-665
15. Kinugawa K, Shimizu T, Yao A, Kohmoto O, Serizawa T, Takahashi T 1997 Transcriptional regulation of inducible nitric oxide synthase in cultured neonatal rat cardiac myocytes. Circ Res 81:911-921
16. Takahashi N, Calderone A, Izzo Jr NJ, Maki TM, Marsh JD, Colucci WS 1994 Hypertrophic stimuli induce transforming growth factor-β1 expression in rat ventricular myocytes. J Clin Invest 94:1470-1476
17. Ikeda U, Kanbe T, Nakayama I, Kawahara Y, Yokoyama M, Shimada K 1995 Aldosterone inhibits nitric oxide synthesis in rat vascular smooth muscle cells induced by interleukin-1β. Eur J Pharmacol 290:69-73
18. Drexler H 1999 Nitric oxide synthases in the failing human heart: a doubled-edged sword? Circulation 99:2972-2975
19. Kunz D, Walker G, Eberhardt W, Pfeilschifter J 1996 Molecular mechanisms of dexamethasone inhibition of nitric oxide synthase expression in interleukin 1β-stimulated mesangial cells: evidence for the involvement of transcriptional and posttranscriptional regulation. Proc Natl Acad Sci USA 93:255-259
20. Katsuyama K, Shichiri M, Kato H, Imai T, Marumo F, Hirata Y 1999 Differential inhibitory actions by glucocorticoid and aspirin on cytokine-induced nitric oxide production in vascular smooth muscle cells. Endocrinology 140:2183-2190
21. Sato A, Liu JP, Funder JW 1997 Aldosterone rapidly represses protein kinase C activity in neonatal rat cardiomyocytes in vitro. Endocrinology 138:3410-3416
22. Brand T, Schneider MD 1995 The TGFβ superfamily in myocardium: ligands, receptors, transduction, and function. J Mol Cell Cardiol 27:5-18
23. Sun Y, Zhang J, Zhang JQ, Ramires FJ 2000 Local angiotensin II and transforming growth factor-β1 in renal fibrosis of rats. Hypertension 35:1078-1084
24. Khalil N 1999 TGF-β: from latent to active. Microbes Infect 1:1255-1263
25. Gray MO, Long CS, Kalinyak JE, Li HT, Karliner JS 1998 Angiotensin II stimulates cardiac myocyte hypertrophy via paracrine release of TGF-β1 and endothelin-1 from fibroblasts. Cardiovasc Res 40:352-363
26. Kelly RA, Balligand JL, Smith TW 1996 Nitric oxide and cardiac function. Circ Res 79:363-380
27. Satoh M, Tamura G, Segawa I, Tashiro A, Hiramori K, Satodate R 1996 Expression of cytokine genes and presence of enteroviral genomic RNA in endomyocardial biopsy tissues of myocarditis and dilated cardiomyopathy. Virchows Arch 427:503-509
28. Neumann FJ, Ott I, Gawaz M, Richardt G, Holzapfel H, Jochum M, Schomig A 1995 Cardiac release of cytokines and inflammatory responses in acute myocardial infarction. Circulation 92:748-755
29. Balligand JL, Kelly RA, Marsden PA, Smith TW, Michel T 1993 Control of cardiac muscle cell function by an endogenous nitric oxide signaling system. Proc Natl Acad Sci USA 90:347-351
30. Funakoshi H, Kubota T, Kawamura N, Machida Y, Feldman AM, Tsutsui H, Shimokawa H, Takeshita A 2002 Disruption of inducible nitric oxide synthase improves β-adrenergic inotropic responsiveness but not the survival of mice with cytokine-induced cardiomyopathy. Circ Res 90:959-965
31. Gealekman O, Abassi Z, Rubinstein I, Winaver J, Binah O 2002 Role of myocardial inducible nitric oxide synthase in contractile dysfunction and β-adrenergic hyporesponsiveness in rats with experimental volume-overload heart failure. Circulation 105:236-243
32. Kanno S, Lee PC, Zhang Y, Ho C, Griffith BP, Shears LL, Billiar TR 2000 Attenuation of myocardial ischemia/reperfusion injury by superinduction of inducible nitric oxide synthase. Circulation 101:2742-2748
33. Farquharson CA, Struthers AD 2000 Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation 101:594-597